Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Takara Bio Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are being handled by 2 distinct examiners, with each examiner responsible for a pending action. This distribution shows that the company's active prosecution is split between different individuals at the USPTO.
The pending actions are located within 1 distinct art unit. This suggests that the biotechnology and pharmaceutical innovations being patented are closely related enough to fall under the same specialized unit, even though they are assigned to different examiners. The busiest examiner for the portfolio is LARA, CAROLINE MONSERRAT, who is currently managing 1 pending office action.
For practitioners, the Takara Bio Inc. portfolio presents a focused technical landscape within the art unit. Because LARA, CAROLINE MONSERRAT and the other distinct examiner each handle a portion of the 2 pending actions, the company must navigate different examination styles within the same unit. This requires a prosecution approach that is technically consistent for the Biotechnology & Pharmaceuticals field but adaptable to the specific requirements of each examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LARA, CAROLINE MONSERRAT | 1 | 100.0% | +0.0% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18847384 | EFFICIENT SYSTEM FOR PRODUCING ADENO-ASSOCIATED VIRUS (AAV) VECTOR | LARA, CAROLINE MONSERRAT | — |
| 17767195 | siRNA EXPRESSION VECTOR | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767195 | siRNA EXPRESSION VECTOR | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18847384 | EFFICIENT SYSTEM FOR PRODUCING ADENO-ASSOCIATED VIRUS (AAV) VECTOR | LARA, CAROLINE MONSERRAT | — | §102§103 | Non-Final OA | — | Pending | Sep 16, 2024 |
| 17767195 | siRNA EXPRESSION VECTOR | SIFFORD, JEFFREY MARK | 1671 | §103§112 | Non-Final OA | — | Pending | Apr 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial